MA38460A1 - Dérivés de la purine en tant qu'agonistes du récepteur cb2 - Google Patents

Dérivés de la purine en tant qu'agonistes du récepteur cb2

Info

Publication number
MA38460A1
MA38460A1 MA38460A MA38460A MA38460A1 MA 38460 A1 MA38460 A1 MA 38460A1 MA 38460 A MA38460 A MA 38460A MA 38460 A MA38460 A MA 38460A MA 38460 A1 MA38460 A1 MA 38460A1
Authority
MA
Morocco
Prior art keywords
receptor agonists
purine derivatives
purine
derivatives
compound
Prior art date
Application number
MA38460A
Other languages
English (en)
Other versions
MA38460B1 (fr
Inventor
Uwe Grether
Atsushi Kimbara
Matthias Nettekoven
Stephan Roever
Mark Rogers-Evans
Tanja Schulz-Gasch
Stefanie Bendels
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA38460A1 publication Critical patent/MA38460A1/fr
Publication of MA38460B1 publication Critical patent/MA38460B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

L'invention concerne un composé de formule (i) où a et r1 à r4 sont définis tels que dans la description et les revendications. Le composé de formule (i) peut être utilisé en tant que médicament
MA38460A 2013-05-02 2014-04-28 Dérivés de la purine en tant qu'agonistes du récepteur cb2 MA38460B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13166293 2013-05-02
PCT/EP2014/058545 WO2014177490A1 (fr) 2013-05-02 2014-04-28 Dérivés de la purine en tant qu'agonistes du récepteur cb2

Publications (2)

Publication Number Publication Date
MA38460A1 true MA38460A1 (fr) 2017-02-28
MA38460B1 MA38460B1 (fr) 2017-10-31

Family

ID=48190399

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38460A MA38460B1 (fr) 2013-05-02 2014-04-28 Dérivés de la purine en tant qu'agonistes du récepteur cb2

Country Status (32)

Country Link
US (1) US9505762B2 (fr)
EP (1) EP2991987B1 (fr)
JP (1) JP6513636B2 (fr)
KR (2) KR102330794B1 (fr)
CN (1) CN105209466B (fr)
AR (1) AR096152A1 (fr)
AU (1) AU2014261585B2 (fr)
BR (1) BR112015027396B1 (fr)
CA (1) CA2903588C (fr)
CL (1) CL2015003195A1 (fr)
CR (1) CR20150511A (fr)
DK (1) DK2991987T3 (fr)
EA (1) EA027497B1 (fr)
ES (1) ES2680935T3 (fr)
HR (1) HRP20181141T1 (fr)
HU (1) HUE039589T2 (fr)
IL (1) IL242160B (fr)
LT (1) LT2991987T (fr)
MA (1) MA38460B1 (fr)
MX (1) MX376599B (fr)
MY (1) MY180050A (fr)
PE (1) PE20151977A1 (fr)
PH (1) PH12015502471A1 (fr)
PL (1) PL2991987T3 (fr)
PT (1) PT2991987T (fr)
RS (1) RS57461B1 (fr)
SG (1) SG11201509014UA (fr)
SI (1) SI2991987T1 (fr)
TR (1) TR201809417T4 (fr)
TW (1) TWI649322B (fr)
UA (1) UA116654C2 (fr)
WO (1) WO2014177490A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015027394A8 (pt) 2013-05-02 2018-01-30 Hoffmann La Roche derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2
AU2014317229B2 (en) 2013-09-06 2018-11-08 F. Hoffmann-La Roche Ag Novel triazolo(4,5-d)pyrimidine derivatives
CA2960794A1 (fr) * 2014-11-07 2016-05-12 F. Hoffmann-La Roche Ag Triazolo[4,5-d]pyrimidines comme agonistes du recepteur cannabinoide 2
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP7090036B2 (ja) 2016-06-23 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー 新規な［１，２，３］トリアゾロ［４，５－ｄ］ピリミジン誘導体
CN109311886B (zh) 2016-06-23 2021-11-09 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
CR20220661A (es) * 2016-06-23 2023-02-21 Hoffmann La Roche NUEVOS DERIVADOS DE [1,2,3]TRIAZOLO[4,5-D]PIRIMIDINA (Divisional 2018-0615)
JP7090037B2 (ja) 2016-06-23 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー 新規な［１，２，３］トリアゾロ［４，５－ｄ］ピリミジン誘導体
EP3388432A1 (fr) * 2017-04-10 2018-10-17 Commissariat à l'Energie Atomique et aux Energies Alternatives Dérivés de purine pour une utilisation comme médicament et dans le traitement de troubles neurodégénératifs ou neuro-inflammatoires
CN115246832B (zh) * 2022-06-15 2024-05-24 深圳湾实验室 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
NZ225447A (en) * 1987-07-20 1991-12-23 Merck & Co Inc Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions
JP2004502642A (ja) 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
EP1492784A4 (fr) 2002-03-28 2006-03-29 Merck & Co Inc 2,3-diphenyl-pyridines substituees
US20030191973A1 (en) * 2002-04-04 2003-10-09 Johnson Carolynn Rae Temporary user suspension of automatic shutdown
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
CN100415747C (zh) * 2002-08-08 2008-09-03 记忆药物公司 磷酸二酯酶4抑制剂
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
WO2009051705A1 (fr) 2007-10-18 2009-04-23 Merck & Co., Inc. 1,2,4-oxadiazoles substitués et leurs analogues comme modulateurs des récepteurs cb2, utiles dans le traitement de la douleur et de maladies respiratoires et non respiratoires
ES2533788T3 (es) * 2008-05-30 2015-04-14 Genentech, Inc. Compuestos inhibidores de PI3K de tipo purina y métodos de uso
WO2010019762A1 (fr) * 2008-08-13 2010-02-18 Jenrin Discovery Composés de purine en tant que bloqueurs de récepteur aux cannabinoïdes
WO2010118367A2 (fr) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Pyrimidines antivirales
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
JP2015521652A (ja) 2012-07-04 2015-07-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ カンナビノイド受容体２アゴニストとしての新規アダマンチル誘導体
ES2643058T3 (es) 2012-12-07 2017-11-21 F. Hoffmann-La Roche Ag Piridina-2-amidas útiles como agonistas de CB2
WO2014086807A1 (fr) 2012-12-07 2014-06-12 F. Hoffmann-La Roche Ag Nouveaux dérivés de pyrazine comme agonistes des récepteurs cb2
SG11201504475QA (en) 2012-12-07 2015-07-30 Hoffmann La Roche Pyridine-2-amides useful as cb2 agonists
LT2928881T (lt) 2012-12-07 2018-06-11 F. Hoffmann-La Roche Ag Nauji piridino dariniai
CN105143220B (zh) 2013-03-07 2018-06-22 豪夫迈·罗氏有限公司 吡唑衍生物

Also Published As

Publication number Publication date
TW201533045A (zh) 2015-09-01
CA2903588C (fr) 2021-10-26
CN105209466A (zh) 2015-12-30
PH12015502471B1 (en) 2016-02-22
HUE039589T2 (hu) 2019-01-28
SI2991987T1 (en) 2018-08-31
MA38460B1 (fr) 2017-10-31
LT2991987T (lt) 2018-08-10
AU2014261585B2 (en) 2018-03-08
EA201591976A1 (ru) 2016-03-31
MX376599B (es) 2025-03-07
BR112015027396B1 (pt) 2023-04-11
JP6513636B2 (ja) 2019-05-15
CR20150511A (es) 2015-11-02
MY180050A (en) 2020-11-20
EP2991987B1 (fr) 2018-05-23
AR096152A1 (es) 2015-12-09
RS57461B1 (sr) 2018-09-28
PT2991987T (pt) 2018-07-13
MX2015014757A (es) 2016-03-11
TWI649322B (zh) 2019-02-01
HK1214245A1 (zh) 2016-07-22
PL2991987T3 (pl) 2018-10-31
PH12015502471A1 (en) 2016-02-22
CL2015003195A1 (es) 2016-06-03
US20160046631A1 (en) 2016-02-18
BR112015027396A2 (pt) 2017-07-25
SG11201509014UA (en) 2015-11-27
KR102330794B1 (ko) 2021-11-26
CA2903588A1 (fr) 2014-11-06
US9505762B2 (en) 2016-11-29
KR20160002871A (ko) 2016-01-08
DK2991987T3 (en) 2018-07-23
AU2014261585A1 (en) 2015-09-17
EA027497B1 (ru) 2017-07-31
HRP20181141T1 (hr) 2018-09-21
PE20151977A1 (es) 2016-01-07
CN105209466B (zh) 2018-05-18
KR20210145303A (ko) 2021-12-01
UA116654C2 (uk) 2018-04-25
NZ712079A (en) 2021-03-26
EP2991987A1 (fr) 2016-03-09
WO2014177490A1 (fr) 2014-11-06
JP2016517872A (ja) 2016-06-20
BR112015027396A8 (pt) 2018-01-30
IL242160B (en) 2019-06-30
ES2680935T3 (es) 2018-09-11
TR201809417T4 (tr) 2018-07-23

Similar Documents

Publication Publication Date Title
MA38460B1 (fr) Dérivés de la purine en tant qu'agonistes du récepteur cb2
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
MA38239A1 (fr) Nouveaux dérivés de pyridine
MA38404A1 (fr) Nouveaux dérivés de pyridine
MA40308A1 (fr) Pyridine-2- amides utiles comme agonistes de cb2
MA38555B1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du récepteur cb2
MA38826B1 (fr) Nouveaux dérivés de triazolo[4,5-d]pyrimidine
MA38238A1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
MA43400B1 (fr) Dérivés de phényle en tant qu'agonistes du récepteur cannabinoïde 2
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA34006B1 (fr) Derives de dihydrofurane utilises comme composes insecticides
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
EP2970119A4 (fr) Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
MA34078B1 (fr) Derives d'arylethynyle
MA35663B1 (fr) Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
MA38583A1 (fr) Dérivés de dolastatine 10 et d'auristatines
MA40281B1 (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
MA37618A1 (fr) Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
AR095097A1 (es) Compuestos de fenoxietoxi
EA201790939A1 (ru) ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2